PubMed Health⌕ Search

Biomedical subjects

T Komita

Publications and source records attributed to T Komita.

8 recordsLinked to original sources
PubMed1993

Intermittent claudication of the spinal cord due to ossification of the ligamentum flavum. A report of two cases.

Two patients are described who developed intermittent claudication of the spinal cord which caused spastic paraparesis during walking. The cause in both was multi-level ossification of the ligamentum flavum. Epidural spinal cord evoked potentials showed disappearance of the third negative component in one case, and positive-going waves in the most compressed area. Both patients had excellent neurological improvement after resection of the ossified ligament.

Adult↗
PubMed1987

[Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group].

We have carried out Phase II study by single oral administration of UFT fine granule preparation consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil(FT-207) and uracil in the molar ratio of 1 : 4. There were 40 evaluable cases out of 54 registered cases, and PR rate was 10.0%. We have observed 2 PR cases out of 14 evaluable cases with stomach cancer, and the response rate was 14.3%. There were PR cases in hepatoma and breast cancer also. Myelosuppression appeared in 10.6% and subjective and objective side effects in 27.1%, in which major symptoms were gastrointestinal disorder similar to those observed in the study of UFT Capsule preparation. We did not observe hepatic and renal malfunctions.

Administration, Oral↗
PubMed1985

[Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].

A phase I study of a new fluorinated pyrimidine compound, 5'-deoxy-5-fluorouridine (5'-DFUR), was performed in 37 patients with various malignant cancers. Starting dose was 600 mg/m2/day (900 mg/body/day) and escalated up to 3900 mg/body/day. The dose given was divided into 3 administrations a day for 5 consecutive days. Subjective symptoms were observed in cases given a dose of over 2,100 mg/body/day. Gastro-intestinal disturbances such as nausea, vomiting and anorexia were the major side effects. In the hematological and urinary examinations, no severe abnormal signs were observed. The maximum tolerated dose was considered to be 2.100 mg/body/day, and the dose-limiting factor was gastro-intestinal disturbance. 5-FU levels were determined in the serum and tumor tissues. 5'-DFUR was well absorbed. The 5-FU level in tumor tissue was very high at 2 to 3 hours post-dose and then rapidly decreased, being 0.05 microgram/g 12 hours after administration. The optimal dosage for a phase II study was suggested to be less than 2,100 mg/body/day.

Administration, Oral↗
PubMed1982

[Clinical experiences with pepleomycin].

From experimental observations, Peplomycin was expected to be more active against a variety of tumors and to be less toxic for the lung than the parent compound. An intermittent dose(10mg. twice a week) of peplomycin was tested in patients with malignant lymphoma or squamous cell carcinoma who had failed conventional treatment. There were two cases of CR and five cases of PR in twelve cases with malignant lymphoma, and two cases of PR in fourteen cases with squamous cell carcinoma. Out of 26 cases treated with peplomycin, fever was seen in ten cases(38.5%) and pulmonary complication was seen in five cases (19.2%). These data obtained from peplomycin treatment were compared with the results obtained from our previous experiences with bleomycin. Response rate, spectrum and frequency of side reactions of peplomycin treatment were substantially identical with those of bleomycin treatment. However, remission duration and life span were much longer in peplomycin treatment. In this respect, peplomycin seems to be superior than bleomycin to a certain extent.

Adult↗
PubMed1982

[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].

Tumor regression was observed in only one patient. Twelve (33%) of the 36 patients reported adverse effects: gastrointestinal symptoms in 8, CNS symptoms in 3, and others in 1. The antitumor efficacy of TAC-278 was insufficient while incidence of adverse effects was similar to other 5-FU derivatives in man and the clinical usefulness of the drug was hardly found. TAC-278 has been developed with an aim to give higher plasma concentrations of 5-FU in man. Even at a dose causing adverse effects, however, the clinical efficacy of TAC-278 was unsatisfactory. The study is a meaning tal eince the results suggest that there might be a more important factor than blood concentration of 5-FU to enhance an antitumor effect of 5-FU derivatives.

Adult↗
PubMed1978

Clinical experiences with aclacinomycin-A.

Aclacinomycin is a new anthracycline analog of adriamycin and daunomycin. Aclacinomycin contains three sugars. The drug has been studied in 22 cases in a phase 1 type of trial on a schedule 20 mg i.v. every other day up to a total of 300 mg. Toxicity has consisted of myelosuppression, nausea and vomiting, and transient hepatic disturbances. Evidence of clinical activity was observed in several cases including a case of breast cancer and gastric cancer. Although no full patial remissions were recorded, further study is continuing.

Animals↗
PubMed1978

Clinical aspects of adriamycin in Japan.

Adriamycin has not been as extensively evaluated in Japan as in some other countries. This is due both to the widespread use of mitomycin C and importantly to the alopecia caused by adriamycin being particularly disturbing to Japanese patients. Japanese studies have shown the drug to be highly active in tumors such as stomach cancer (31/92), lung cancer (27/84), and malignant lymphomas (15/46). Combination studies have been mainly with 5-FU although others have also been investigated. Other approaches which have been studied include intraarterial infusion, local application in bladder cancer, intrapleural application and in the treatment of childhood malignancies.

Doxorubicin↗